AstraZeneca

Diversified pharma

AZN · Nasdaq · United Kingdom

Share price · AZN

$178.76+18.66 (+11.66%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.5M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AZN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+7.0%
  2. 3 Aug 2026-6.9%
  3. 10 Jul 2026-3.9%
  4. 9 Jul 2026-5.7%
  5. 2 Jul 2026+6.1%
  6. 1 Jul 2026-3.0%
  7. 27 Mar 2026+2.7%
  8. 11 Feb 2026+5.9%
  9. 10 Feb 2026+2.9%
  10. 20 Jan 2026-4.7%

Share of unusual movement by asset

For each asset, the share of AZN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Datopotamab Deruxtecan
events and moves
157%
Acalabrutinib
events and moves
84%
Savolitinib (Orpathys)
events and moves
203%
Trastuzumab Deruxtecan
events and moves
163%
tezepelumab (Tezspire)
events and moves
82%
Camizestrant (Etcamah)
events and moves
81%
Osimertinib (Tagrisso)
events and moves
7shown from 8 days
Baxdrostat (Baxfendy)
events and moves
5shown from 8 days
Anifrolumab
events and moves
5shown from 8 days
Sunvozertinib (Zegfrovy)
events and moves
5shown from 8 days
Ravulizumab (Ultomiris)
events and moves
4shown from 8 days
tozorakimab
events and moves
4shown from 8 days
Durvalumab
events and moves
4shown from 8 days
Capivasertib
events and moves
4shown from 8 days
Benralizumab (Fasenra)
events and moves
3shown from 8 days
Roxadustat (Evrenzo)
events and moves
3shown from 8 days
Eplontersen (Wainua)
events and moves
2shown from 8 days
Tremelimumab
events and moves
2shown from 8 days
elecoglipron
events and moves
1shown from 8 days
Pexerelgon
events and moves
1shown from 8 days
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere)
events and moves
1shown from 8 days
Dapagliflozin (Farxiga / Forxiga)
events and moves
1shown from 8 days
tralokinumab (Adbry)
events and moves
1shown from 8 days
Laroprovstat
events and moves
1shown from 8 days
Volrustomig
events and moves
1shown from 8 days
Ceralasertib
events and moves
1shown from 8 days
alvelestat
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—14%
Other company news (earnings, financing, releases naming no asset)—33%
Sessions with no dated event—34%

Assets

(114 total)
114Total Assets
36Approved
25Phase 3 / Filed
53Phase 1–2 / Early
73Diseases
Quick filter:
Showing 114 of 114 assets
Target & Modality
Approved
BTKSmall molecule
Diffuse Large B-Cell LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Approved
Beta-2 adrenergic receptor · Glucocorticoid receptorCombination
Asthma
Approved
AromataseSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis
Baxdrostat(Baxfendy)
Approved
Aldosterone synthase (CYP11B2)Small molecule
HypertensionHeart FailureChronic Kidney Disease
Benralizumab(Fasenra)
Approved
IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody
Asthma
Budesonide(Pulmicort)
Approved
Glucocorticoid receptor agonistSmall molecule
Asthma
Approved
Glucocorticoid receptor; Beta-2 adrenergic receptorCombination
Chronic Obstructive Pulmonary DiseaseAsthma
Approved
Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicSmall molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Camizestrant(Etcamah)
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
AKT (inhibitor)Small molecule
Breast CancerProstate Cancer
HR+/HER2- Metastatic Breast Cancer
Dapagliflozin(Farxiga / Forxiga)
Approved
SGLT2Small molecule
Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
Approved
TROP2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerBladder / Urothelial Cancer
HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma
Approved
PD-L1Monoclonal antibody
Non-Small Cell Lung CancerOvarian CancerHepatocellular CarcinomaBladder CancerBiliary Tract CancerSmall Cell Lung CancerBladder / Urothelial CancerRenal Cell CarcinomaEndometrial Cancer
Urothelial Carcinoma, Non-Muscle Invasive Bladder Cancer
Eplontersen(Wainua)
Approved
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy

Upcoming events

(227 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
November 2026 (2)
AZD0754Phase 1/2Metastatic Prostate Cancer
Est. primary completion 2026-11-24 · NCT06267729 · CT.gov ↗
What to watch
Durvalumab + TremelimumabPhase 2Hepatocellular Carcinoma
Est. primary completion 2026-11-30 · NCT07081633 · CT.gov ↗
What to watch
December 2026 (6)
Dapagliflozin · Farxiga / Forxiga + Baxdrostat · BaxfendyPhase 2Chronic Kidney Disease and Hypertension
Est. primary completion 2026-12-10 · NCT07222917 · CT.gov ↗
What to watch
Gefurulimab · KlygefaPhase 3Generalized Myasthenia Gravis, gMG
Est. primary completion 2026-12-15 · NCT06607627 · CT.gov ↗
What to watch
Zadavotide guraxetanPhase 2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2026-12-23 · NCT06402331 · CT.gov ↗
What to watch
Est. primary completion 2026-12-23 · NCT05692180 · CT.gov ↗
What to watch
JAB-23E73Phase 1/2Advanced Solid Tumor
Est. primary completion 2026-12-31 · NCT06959615 · CT.gov ↗
What to watch
DurvalumabPhase 3Cancer
Est. primary completion 2026-12-31 · NCT05303532 · CT.gov ↗
What to watch
2027 (79)
January 2027 (7)
LaroprovstatPhase 3Heterozygous Familial Hypercholesterolaemia
Est. primary completion 2027-01-04 · NCT07000136 · CT.gov ↗
What to watch
AnifrolumabPhase 3Systemic Sclerosis, Scleroderma
Est. primary completion 2027-01-06 · NCT05925803 · CT.gov ↗
What to watch
LaroprovstatPhase 3Cardiovascular Disease
Est. primary completion 2027-01-11 · NCT07000123 · CT.gov ↗
What to watch
Osimertinib · Tagrisso + Datopotamab DeruxtecanPhase 3Metastatic Non-small Cell Lung Cancer
Est. primary completion 2027-01-11 · NCT06417814 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2027-01-13 · NCT06706817 · CT.gov ↗
What to watch
Est. primary completion 2027-01-18 · NCT05374603 · CT.gov ↗
What to watch
Lenbelintide + AZD9550Phase 1/2Overweight and Obesity
Est. primary completion 2027-01-29 · NCT06151964 · CT.gov ↗
What to watch
February 2027 (10)
TQC3721Phase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-02 · NCT07464587 · CT.gov ↗
What to watch
AZD0120Phase 1/2Refractory Systemic Lupus Erythematosus
Est. primary completion 2027-02-01 · NCT06530849 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 2Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Est. primary completion 2027-02-10 · NCT06271837 · CT.gov ↗
What to watch
AZD4144Phase 2Sepsis, Acute Kidney Injury
Est. primary completion 2027-02-11 · NCT07215702 · CT.gov ↗
What to watch
AcalabrutinibPhase 3Lymphoma, Mantle Cell
Est. primary completion 2027-02-15 · NCT02972840 · CT.gov ↗
What to watch
Zibotentan + DapagliflozinPhase 3Chronic Kidney Disease With High Proteinuria
Est. primary completion 2027-02-18 · NCT06087835 · CT.gov ↗
What to watch
LaroprovstatPhase 2/3Dyslipidaemia
Est. primary completion 2027-02-22 · NCT06834932 · CT.gov ↗
What to watch
Est. primary completion 2027-02-22 · NCT05629234 · CT.gov ↗
What to watch
AcalabrutinibPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2027-02-22 · NCT04529772 · CT.gov ↗
What to watch
AnifrolumabPhase 3Lupus Nephritis
Est. primary completion 2027-02-23 · NCT05138133 · CT.gov ↗
What to watch
March 2027 (3)
TQC3721Phase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-03 · NCT07147946 · CT.gov ↗
What to watch
AZD7760Phase 1/2Staphylococcus Aureus
Est. primary completion 2027-03-08 · NCT06749457 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric …
Est. primary completion 2027-03-23 · NCT04482309 · CT.gov ↗
What to watch
April 2027 (5)
OlaparibPhase 3Ovarian Cancer, Breast Cancer
Est. primary completion 2027-04-06 · NCT04421963 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / Forxiga + BalcinrenonePhase 3Heart Failure and Impaired Kidney Function
Est. primary completion 2027-04-16 · NCT06307652 · CT.gov ↗
What to watch
AZD5148Phase 2Clostridioides Difficile Infection
Est. primary completion 2027-04-20 · NCT07285213 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 3Breast Cancer, Early Breast Cancer
Est. primary completion 2027-04-20 · NCT05774951 · CT.gov ↗
What to watch
AcalabrutinibPhase 3Chronic Lymphocytic Leukemia
Est. primary completion 2027-04-30 · NCT03836261 · CT.gov ↗
What to watch
May 2027 (7)
Olaparib + Zadavotide guraxetanPhase 2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2027-05 · NCT06909825 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Breast Cancer; HER2-positive; Metastatic
Est. primary completion 2027-05-03 · NCT04784715 · CT.gov ↗
What to watch
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
OlaparibPhase 3Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + Saruparib + Trastuzumab Deruxtecan + Camizestrant · EtcamahPhase 1/2Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5 …
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Est. primary completion 2027-05-28 · NCT06449001 · CT.gov ↗
What to watch
Rosuvastatin + laroprovstat/rosuvastatinPhase 3Hypercholesterolaemia
Est. primary completion 2027-05-28 · NCT07619118 · CT.gov ↗
What to watch
June 2027 (6)
tozorakimabPhase 2Asthma
Est. primary completion 2027-06-07 · NCT06932263 · CT.gov ↗
What to watch
Est. primary completion 2027-06-25 · NCT06473779 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 1/2ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
Est. primary completion 2027-06-30 · NCT06188520 · CT.gov ↗
What to watch
AZD9793Phase 1/2Hepatocellular Carcinoma
Est. primary completion 2027-06-30 · NCT06795022 · CT.gov ↗
What to watch
VolrustomigPhase 2Metastatic Colorectal Cancer
Est. primary completion 2027-06-30 · NCT06792695 · CT.gov ↗
What to watch
DurvalumabPhase 3Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-30 · NCT04550260 · CT.gov ↗
What to watch
July 2027 (7)
ALXN1920Phase 2Primary Membranous Nephropathy
Est. primary completion 2027-07-02 · NCT07157787 · CT.gov ↗
What to watch
AZD2389Phase 2Liver Fibrosis, Hepatic Cirrhosis
Est. primary completion 2027-07-07 · NCT07610837 · CT.gov ↗
What to watch
AcalabrutinibPhase 3Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Est. primary completion 2027-07-15 · NCT05057494 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Primary Hyperaldosteronism
Est. primary completion 2027-07-27 · NCT07007793 · CT.gov ↗
What to watch
Durvalumab + Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-07-28 · NCT06103864 · CT.gov ↗
What to watch
VolrustomigPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
Laroprovstat + Rosuvastatin + laroprovstat/rosuvastatinPhase 3Hypercholesterolaemia
Est. primary completion 2027-07-30 · NCT07619131 · CT.gov ↗
What to watch
August 2027 (3)
Osimertinib · TagrissoPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-08-02 · NCT05120349 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3Generalized Myasthenia Gravis, gMG
Est. primary completion 2027-08-24 · NCT07596784 · CT.gov ↗
What to watch
AZD6793Phase 2Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2027-08-31 · NCT07082738 · CT.gov ↗
What to watch
September 2027 (3)
Durvalumab + Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-09-01 · NCT05629585 · CT.gov ↗
What to watch
Rilvegostomig + Saruparib + Puxitatug samrotecan + PalacaparibPhase 1/2Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Est. primary completion 2027-09-29 · NCT05123482 · CT.gov ↗
What to watch
SaruparibPhase 3Metastatic Castration-Sensitive Prostate Cancer
Est. primary completion 2027-09-30 · NCT06120491 · CT.gov ↗
What to watch
October 2027 (14)
AZD0120Phase 1/2Relapsed/Refractory Multiple Myeloma
Est. primary completion 2027-10-01 · NCT05850234 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 2Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-10-01 · NCT05801029 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + Volrustomig + RilvegostomigPhase 2Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer …
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2027-10-01 · NCT05950945 · CT.gov ↗
What to watch
OpemalirsenPhase 2APOL1-Mediated Kidney Disease
Est. primary completion 2027-10-04 · NCT06824987 · CT.gov ↗
What to watch
Est. primary completion 2027-10-04 · NCT06471257 · CT.gov ↗
What to watch
ALXN1820Phase 2Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Est. primary completion 2027-10-11 · NCT07160608 · CT.gov ↗
What to watch
CevolisiranPhase 2Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Est. primary completion 2027-10-11 · NCT06744647 · CT.gov ↗
What to watch
Laroprovstat + Rosuvastatin + laroprovstat/rosuvastatinPhase 3Hypercholesterolemia
Est. primary completion 2027-10-11 · NCT07930507 · CT.gov ↗
What to watch
Est. primary completion 2027-10-13 · NCT06307665 · CT.gov ↗
What to watch
Puxitatug samrotecanPhase 3Endometrial Cancer, Malignant Solid Tumour
Est. primary completion 2027-10-15 · NCT07044336 · CT.gov ↗
What to watch
OlaparibPhase 1/2Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
OlaparibPhase 3Small Cell Lung Cancer
Est. primary completion 2027-10-28 · NCT04624204 · CT.gov ↗
What to watch
Roxadustat · EvrenzoPhase 3Chronic Kidney Disease, Renal Anemia
Est. primary completion 2027-10-30 · NCT05970172 · CT.gov ↗
What to watch
November 2027 (9)
Est. primary completion 2027-11-01 · NCT05687266 · CT.gov ↗
What to watch
CapivasertibPhase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
tozorakimabPhase 3Viral Lung Infection and Acute Respiratory Failure
Est. primary completion 2027-11-04 · NCT05624450 · CT.gov ↗
What to watch
Rilvegostomig + Trastuzumab Deruxtecan + Sonesitatug vedotinPhase 2Gastroesophageal Adenocarcinoma
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
AZD1163Phase 2Rheumatoid Arthritis
Est. primary completion 2027-11-12 · NCT07276581 · CT.gov ↗
What to watch
VolrustomigPhase 3Locally Advanced Cervical Cancer
Est. primary completion 2027-11-26 · NCT06079671 · CT.gov ↗
What to watch
Est. primary completion 2027-11-30 · NCT05702229 · CT.gov ↗
What to watch
Capivasertib + Fulvestrant · FaslodexPhase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-11-30 · NCT06764186 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3Delayed Graft Function, DGF, Kidney Transplant
Est. primary completion 2027-11-30 · NCT06830798 · CT.gov ↗
What to watch
December 2027 (5)
Budesonide/glycopyrrolate/formoterol fumarate · Breztri AerospherePhase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-12-03 · NCT06283966 · CT.gov ↗
What to watch
CliramitugPhase 3Transthyretin Amyloid Cardiomyopathy
Est. primary completion 2027-12-06 · NCT06183931 · CT.gov ↗
What to watch
AZD0292Phase 2Bronchiectasis With Pseudomonas Aeruginosa Colonization
Est. primary completion 2027-12-09 · NCT07088926 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 2Advanced Breast Cancer
Est. primary completion 2027-12-28 · NCT07427394 · CT.gov ↗
What to watch
AcalabrutinibPhase 2Mantle-cell Lymphoma
Est. primary completion 2027-12-31 · NCT07029737 · CT.gov ↗
What to watch
2028 (57)
January 2028 (4)
SurovatamigPhase 1/2B-cell Acute Lymphoblastic Leukemia (B-ALL)
Est. primary completion 2028-01-06 · NCT06137118 · CT.gov ↗
What to watch
AnifrolumabPhase 3Polymyositis, Dermatomyositis
Est. primary completion 2028-01-10 · NCT06455449 · CT.gov ↗
What to watch
AZD0292Phase 2Bronchiectasis With Pseudomonas Aeruginosa Colonization
Est. primary completion 2028-01-18 · NCT07774403 · CT.gov ↗
What to watch
Vemzatatug vedotinPhase 1/2Multiple Myeloma
Est. primary completion 2028-01-24 · NCT06106945 · CT.gov ↗
What to watch
February 2028 (8)
Datopotamab DeruxtecanPhase 3Breast Cancer
Est. primary completion 2028-02-02 · NCT07205822 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + Trastuzumab Deruxtecan + PalacaparibPhase 1/2Advanced Solid Malignancies
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3Severe Asthma
Est. primary completion 2028-02-07 · NCT07363642 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Uncontrolled Hypertension
Est. primary completion 2028-02-09 · NCT07686120 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Advanced Cancer, Metastatic Cancer
Est. primary completion 2028-02-17 · NCT06174987 · CT.gov ↗
What to watch
Benralizumab · FasenraPhase 3Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Est. primary completion 2028-02-20 · NCT06512883 · CT.gov ↗
What to watch
AZD0120Phase 1/2Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Est. primary completion 2028-02-22 · NCT07295847 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / Forxiga + Baxdrostat · BaxfendyPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2028-02-24 · NCT06268873 · CT.gov ↗
What to watch
March 2028 (3)
tezepelumab · TezspirePhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2028-03-01 · NCT07520162 · CT.gov ↗
What to watch
VolrustomigPhase 2Locally Advanced Cervical Cancer
Est. primary completion 2028-03-13 · NCT06943833 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-03-21 · NCT06350097 · CT.gov ↗
What to watch
April 2028 (2)
elecoglipronPhase 3Obesity, Overweight
Est. primary completion 2028-04-06 · NCT07775404 · CT.gov ↗
What to watch
SurovatamigPhase 2B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
Est. primary completion 2028-04-21 · NCT06526793 · CT.gov ↗
What to watch
May 2028 (4)
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-05-23 · NCT07662213 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-05-23 · NCT07664553 · CT.gov ↗
What to watch
Savolitinib · OrpathysPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-05-30 · NCT05009836 · CT.gov ↗
What to watch
Est. primary completion 2028-05-31 · NCT06023589 · CT.gov ↗
What to watch
June 2028 (5)
Sunvozertinib · ZegfrovyPhase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2028-06 · NCT07079475 · CT.gov ↗
What to watch
RilvegostomigPhase 1/2Non-Small-Cell Lung Carcinoma
Est. primary completion 2028-06-01 · NCT04995523 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Gastric Cancer, Gastroesophageal Junction Cancer
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Rilvegostomig + Trastuzumab DeruxtecanPhase 3Biliary Tract Cancer
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
AZD0120Phase 3Relapsed Refractory Multiple Myeloma
Est. primary completion 2028-06-14 · NCT07391657 · CT.gov ↗
What to watch
July 2028 (5)
Surovatamig + AZD4512Phase 1/2B-cell Non-Hodgkin Lymphoma
Est. primary completion 2028-07-04 · NCT07123454 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-07-05 · NCT07662109 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
Est. primary completion 2028-07-13 · NCT07662135 · CT.gov ↗
What to watch
elecoglipron + Dapagliflozin · Farxiga / ForxigaPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-07-14 · NCT07662044 · CT.gov ↗
What to watch
elecoglipronPhase 3Weight Management
Est. primary completion 2028-07-31 · NCT07667803 · CT.gov ↗
What to watch
August 2028 (6)
Saruparib + Torvutatug samrotecan + PalacaparibPhase 1/2Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
Est. primary completion 2028-08-04 · NCT05797168 · CT.gov ↗
What to watch
LenbelintidePhase 3Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Est. primary completion 2028-08-09 · NCT07776509 · CT.gov ↗
What to watch
LenbelintidePhase 3Obesity or Overweight, Diabetes Mellitus, Type 2
Est. primary completion 2028-08-09 · NCT07784270 · CT.gov ↗
What to watch
LenbelintidePhase 3Obesity or Overweight
Est. primary completion 2028-08-11 · NCT07784725 · CT.gov ↗
What to watch
AnifrolumabPhase 3Lupus Erythematosus, Systemic
Est. primary completion 2028-08-25 · NCT07751848 · CT.gov ↗
What to watch
DurvalumabPhase 2Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine
Est. primary completion 2028-08-30 · NCT06960577 · CT.gov ↗
What to watch
September 2028 (3)
LenbelintidePhase 3Obesity, Overweight, Type 2 Diabetes Mellitus
Est. primary completion 2028-09-15 · NCT07922330 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3NMOSD, Neuromyelitis Optica Spectrum Disorder
Est. primary completion 2028-09-19 · NCT07557420 · CT.gov ↗
What to watch
Torvutatug samrotecanPhase 3Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer …
Est. primary completion 2028-09-29 · NCT07816666 · CT.gov ↗
What to watch
October 2028 (5)
AnifrolumabPhase 3Systemic Lupus Erythematosus
Est. primary completion 2028-10-05 · NCT05835310 · CT.gov ↗
What to watch
AZD4512Phase 1/2B-cell Acute Lymphoblastic Leukemia (B-ALL)
Est. primary completion 2028-10-11 · NCT07109219 · CT.gov ↗
What to watch
SurovatamigPhase 2Primary Membranous Nephropathy
Est. primary completion 2028-10-13 · NCT07571746 · CT.gov ↗
What to watch
AcalabrutinibPhase 2Mantle Cell Lymphoma (MCL)
Est. primary completion 2028-10-31 · NCT05951959 · CT.gov ↗
What to watch
Osimertinib · Tagrisso + DurvalumabPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-10-31 · NCT03833154 · CT.gov ↗
What to watch
November 2028 (9)
JAB-23E73Phase 1/2Advanced Solid Tumors
Est. primary completion 2028-11 · NCT06973564 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Ovarian Cancer
Est. primary completion 2028-11-01 · NCT06819007 · CT.gov ↗
What to watch
AZD0120Phase 3Newly Diagnosed Multiple Myeloma (NDMM)
Est. primary completion 2028-11-02 · NCT07735637 · CT.gov ↗
What to watch
VolrustomigPhase 3Unresectable Pleural Mesothelioma
Est. primary completion 2028-11-16 · NCT06097728 · CT.gov ↗
What to watch
Torvutatug samrotecanPhase 3Epithelial Ovarian Cancer
Est. primary completion 2028-11-17 · NCT07218809 · CT.gov ↗
What to watch
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis …
Est. primary completion 2028-11-29 · NCT07024563 · CT.gov ↗
What to watch
VolrustomigPhase 2Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) …
Est. primary completion 2028-11-30 · NCT06535607 · CT.gov ↗
What to watch
Durvalumab + OlaparibPhase 3Advanced or Recurrent Endometrial Cancer
Est. primary completion 2028-11-30 · NCT06746116 · CT.gov ↗
What to watch
December 2028 (3)
Datopotamab Deruxtecan + AZD3470Phase 1/2Advanced Solid Tumors That Are MTAP Deficient
Est. primary completion 2028-12-04 · NCT06130553 · CT.gov ↗
What to watch
Durvalumab + Datopotamab DeruxtecanPhase 2Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-12-16 · NCT07941609 · CT.gov ↗
What to watch
tozorakimabPhase 3Chronic Obstructive Pulmonary Disease, COPD
Est. primary completion 2028-12-29 · NCT07566195 · CT.gov ↗
What to watch
2029 (50)
January 2029 (7)
RilvegostomigPhase 3Biliary Tract Cancer
Est. primary completion 2029-01-02 · NCT06109779 · CT.gov ↗
What to watch
AZD0120Phase 3Newly Diagnosed Multiple Myeloma
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
OlaparibPhase 1/2Prostatic Neoplasms, Castration-Resistant
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
AZD0516 + PalacaparibPhase 1/2Metastatic Prostate Cancer
Est. primary completion 2029-01-18 · NCT07181161 · CT.gov ↗
What to watch
Rilvegostomig + Trastuzumab DeruxtecanPhase 3Endometrial Cancer
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
AnifrolumabPhase 3Systemic Lupus Erythematosus
Est. primary completion 2029-01-26 · NCT07430306 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2029-01-29 · NCT07291037 · CT.gov ↗
What to watch
February 2029 (4)
CliramitugPhase 2Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Est. primary completion 2029-02-06 · NCT07608354 · CT.gov ↗
What to watch
AZD3632Phase 1/2Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
Est. primary completion 2029-02-15 · NCT07155226 · CT.gov ↗
What to watch
RilvegostomigPhase 1/2Advanced or Metastatic Non-small Cell Lung Cancer
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 3ER-Positive HER2-Negative Breast Cancer
Est. primary completion 2029-02-28 · NCT07647328 · CT.gov ↗
What to watch
March 2029 (4)
tezepelumab · TezspirePhase 3Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2029-03-13 · NCT06878261 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2029-03-13 · NCT06883305 · CT.gov ↗
What to watch
Rilvegostomig + AZD5863Phase 1/2Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Est. primary completion 2029-03-16 · NCT06005493 · CT.gov ↗
What to watch
AZD6621Phase 1/2Prostate Cancer
Est. primary completion 2029-03-29 · NCT07192614 · CT.gov ↗
What to watch
April 2029 (3)
Datopotamab Deruxtecan + RilvegostomigPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
AcalabrutinibPhase 2Diffuse Large B-Cell Lymphoma
Est. primary completion 2029-04-22 · NCT05952024 · CT.gov ↗
What to watch
Rilvegostomig + Trastuzumab DeruxtecanPhase 3HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
May 2029 (6)
AZD0120Phase 1/2Lupus Erythematosus, Systemic
Est. primary completion 2029-05-01 · NCT06897930 · CT.gov ↗
What to watch
AcalabrutinibPhase 2Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Est. primary completion 2029-05-01 · NCT07024706 · CT.gov ↗
What to watch
AZD3470Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Est. primary completion 2029-05-03 · NCT06137144 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3Metastatic Non Small Cell Lung Cancer
Est. primary completion 2029-05-11 · NCT05555732 · CT.gov ↗
What to watch
Est. primary completion 2029-05-23 · NCT07525375 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 2Lung Cancer
Est. primary completion 2029-05-30 · NCT07295821 · CT.gov ↗
What to watch
June 2029 (4)
Datopotamab DeruxtecanPhase 2/3Urothelial Cancer, Bladder Cancer
Est. primary completion 2029-06-01 · NCT07129993 · CT.gov ↗
What to watch
Zadavotide guraxetanPhase 3Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2029-06-04 · NCT07611110 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 2Non-small Cell Lung Cancer
Est. primary completion 2029-06-30 · NCT05546866 · CT.gov ↗
What to watch
DurvalumabPhase 3Small Cell Lung Carcinoma
Est. primary completion 2029-06-30 · NCT06992609 · CT.gov ↗
What to watch
July 2029 (2)
Est. primary completion 2029-07-30 · NCT07934420 · CT.gov ↗
What to watch
RilvegostomigPhase 3Biliary Tract Cancer
Est. primary completion 2029-07-31 · NCT07221253 · CT.gov ↗
What to watch
August 2029 (4)
Eplontersen · WainuaPhase 3Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Est. primary completion 2029-08 · NCT05071300 · CT.gov ↗
What to watch
Eplontersen · WainuaPhase 3Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Est. primary completion 2029-08 · NCT05667493 · CT.gov ↗
What to watch
AZD0120Phase 1/2Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Est. primary completion 2029-08-15 · NCT07081646 · CT.gov ↗
What to watch
Rilvegostomig + Sonesitatug vedotinPhase 3Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
September 2029 (4)
Sunvozertinib · ZegfrovyPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-09 · NCT07182682 · CT.gov ↗
What to watch
elecoglipronPhase 3Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Est. primary completion 2029-09-03 · NCT07761117 · CT.gov ↗
What to watch
Zadavotide guraxetan + PalacaparibPhase 1/2Metastatic Prostate Cancer
Est. primary completion 2029-09-25 · NCT07590934 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 1/2Urothelial Cancer, Non-small Cell Lung Cancer
Est. primary completion 2029-09-30 · NCT07890714 · CT.gov ↗
What to watch
October 2029 (2)
Rilvegostomig + AZD6750Phase 1/2Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma …
Est. primary completion 2029-10-02 · NCT07115043 · CT.gov ↗
What to watch
LaroprovstatPhase 3Cardiovascular Disease
Est. primary completion 2029-10-26 · NCT07000357 · CT.gov ↗
What to watch
November 2029 (2)
DurvalumabPhase 3Gastric, Esophagogastric Junction
Est. primary completion 2029-11-01 · NCT07877818 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 2Stage II-IIIB Non-small Cell Lung Carcinoma
Est. primary completion 2029-11-22 · NCT05526755 · CT.gov ↗
What to watch
December 2029 (8)
Est. primary completion 2029-12-17 · NCT06677060 · CT.gov ↗
What to watch
AZD5492Phase 1/2B-cell Malignancies
Est. primary completion 2029-12-18 · NCT06542250 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / Forxiga + Baxdrostat · BaxfendyPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2029-12-18 · NCT06742723 · CT.gov ↗
What to watch
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
Benralizumab · FasenraPhase 3Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Est. primary completion 2029-12-27 · NCT07444567 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + RilvegostomigPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
JAB-23E73Phase 1/2Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2029-12-31 · NCT07640295 · CT.gov ↗
What to watch
OlaparibPhase 2Breast Neoplasms, Breast Cancer
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (23)
January 2030 (1)
RilvegostomigPhase 3Carcinoma, Non-Small Cell Lung
Est. primary completion 2030-01-17 · NCT06868277 · CT.gov ↗
What to watch
February 2030 (2)
Est. primary completion 2030-02-21 · NCT03813407 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Endometrial Cancer
Est. primary completion 2030-02-26 · NCT07022483 · CT.gov ↗
What to watch
March 2030 (4)
Datopotamab DeruxtecanPhase 3Metastatic Non Small Cell Lung Cancer
Est. primary completion 2030-03-04 · NCT05215340 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 3Breast Cancer, Early Breast Cancer
Est. primary completion 2030-03-04 · NCT05952557 · CT.gov ↗
What to watch
Rilvegostomig + TremelimumabPhase 3Hepatocellular Carcinoma
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
Saruparib + AZD4956Phase 1/2Solid Tumours
Est. primary completion 2030-03-29 · NCT07446855 · CT.gov ↗
What to watch
April 2030 (2)
VolrustomigPhase 3Locally Advanced Head and Neck Squamous Cell Carcinoma
Est. primary completion 2030-04-17 · NCT06129864 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
May 2030 (2)
Acalabrutinib + SurovatamigPhase 1/2Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Est. primary completion 2030-05-20 · NCT06564038 · CT.gov ↗
What to watch
Durvalumab + Datopotamab Deruxtecan + Volrustomig + Rilvegostomig + FalbikitugPhase 2Non-small Cell Lung Cancer
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
June 2030 (2)
SurovatamigPhase 3Large B-cell Lymphoma
Est. primary completion 2030-06-10 · NCT07215585 · CT.gov ↗
What to watch
Torvutatug samrotecanPhase 3Epithelial Ovarian Cancer
Est. primary completion 2030-06-28 · NCT07851025 · CT.gov ↗
What to watch
July 2030 (4)
Dapagliflozin · Farxiga / Forxiga + BalcinrenonePhase 3Renal Insufficiency, Chronic
Est. primary completion 2030-07-01 · NCT07624305 · CT.gov ↗
What to watch
RilvegostomigPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
CliramitugPhase 3Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Est. primary completion 2030-07-11 · NCT07789483 · CT.gov ↗
What to watch
September 2030 (4)
Roxadustat · EvrenzoPhase 3Myelodysplastic Syndromes
Est. primary completion 2030-09 · NCT07722988 · CT.gov ↗
What to watch
AnifrolumabPhase 2Systemic Lupus Erythematosus
Est. primary completion 2030-09-02 · NCT07630714 · CT.gov ↗
What to watch
SurovatamigPhase 3Large B-cell Lymphoma
Est. primary completion 2030-09-02 · NCT07911553 · CT.gov ↗
What to watch
Datopotamab Deruxtecan + RilvegostomigPhase 3High-risk Muscle Invasive Urothelial Carcinoma
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
October 2030 (1)
elecoglipronPhase 3Chronic Kidney Disease
Est. primary completion 2030-10-04 · NCT07753993 · CT.gov ↗
What to watch
November 2030 (1)
RilvegostomigPhase 3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2030-11-18 · NCT06627647 · CT.gov ↗
What to watch
2031 (5)
March 2031 (1)
AZD4045Phase 1/2Relapsed or Refractory Multiple Myeloma
Est. primary completion 2031-03-06 · NCT07681596 · CT.gov ↗
What to watch
April 2031 (1)
SaruparibPhase 1/2Metastatic Prostate Cancer
Est. primary completion 2031-04-11 · NCT05367440 · CT.gov ↗
What to watch
May 2031 (1)
SaruparibPhase 3Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Est. primary completion 2031-05-30 · NCT07711002 · CT.gov ↗
What to watch
August 2031 (1)
SurovatamigPhase 3Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Est. primary completion 2031-08-29 · NCT07509151 · CT.gov ↗
What to watch
November 2031 (1)
SurovatamigPhase 3Untreated Follicular Lymphoma
Est. primary completion 2031-11-26 · NCT06549595 · CT.gov ↗
What to watch
2032 (2)
January 2032 (1)
ALXN2350Phase 1/2BAG3 Mutation Associated Dilated Cardiomyopathy
Est. primary completion 2032-01-27 · NCT07218887 · CT.gov ↗
What to watch
December 2032 (1)
AnifrolumabPhase 3Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Est. primary completion 2032-12-30 · NCT07691970 · CT.gov ↗
What to watch
2033 (2)
March 2033 (2)
OlaparibPhase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
SaruparibPhase 3Prostate Cancer
Est. primary completion 2033-03-31 · NCT06952803 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
OlaparibPhase 3Solid Tumors, Hematologic Malignancies
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(50)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

Q1 2027FDA action datetozorakimabTozorakimab PDUFA date expected Q1 2027
US, FDA · AstraZeneca · Source ↗

Recent

13 November 2026ApprovalDurvalumabFDA approves perioperative Imfinzi with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer
US, FDA · Source ↗
27 October 2026ApprovalTrastuzumab DeruxtecanEU approves Enhertu as adjuvant monotherapy in HER2-positive early breast cancer
EU, EC · Source ↗
26 October 2026PresentationsavolitinibSANOVO Phase III results at ESMO 2026 (LBA69)
China · HUTCHMED · Source ↗
25 October 2026PresentationsavolitinibSAFFRON primary results at ESMO 2026 Presidential Symposium (LBA6)
Global · HUTCHMED · Source ↗
21 October 2026ApprovalRavulizumabFDA grants accelerated approval to Ultomiris in IgA nephropathy
US, FDA · Source ↗
12 October 2026Topline resulttozorakimabPROSPERO (NCT05742802) Phase III extension missed its primary endpoint
AstraZeneca · Source ↗
October 2026ApprovalRavulizumabFDA Boxed Warning on Ultomiris (BLA761108)
US, FDA · FDA · Source ↗
29 September 2026Filing submittedsavolitinibUS NDA submitted for savolitinib plus osimertinib
US, FDA · AstraZeneca · Source ↗
14 September 2026Topline resultTrastuzumab DeruxtecanDESTINY-Lung04: Enhertu met its PFS primary endpoint vs pembrolizumab plus chemotherapy
AstraZeneca; Daiichi Sankyo · Source ↗
8 September 2026Priority reviewtozorakimabFDA accepts tozorakimab BLA under Priority Review
US, FDA · AstraZeneca · Source ↗
4 September 2026ApprovalCamizestrantFDA Boxed Warning on Etcamah (NDA220359)
US, FDA · FDA · Source ↗
1 September 2026ApprovalTrastuzumab DeruxtecanEnhertu with pertuzumab approved in the EU for first-line HER2-positive metastatic breast cancer
EU, EC/EMA · Source ↗

The 12 most recent of 49 past events are shown.

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$15.3B$3.5B$7.6B—report ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4$15.5B$3.9B$5.7B—report ↗
2025-Q3$15.2B$3.7B$8.2B—report ↗
2025-Q2$14.5B$3.5B$7.1B—report ↗
2025-Q1$13.6B$3.2B$5.4B—report ↗
2024-Q4$14.9B$4.7B$5.7B—report ↗
2024-Q3$13.6B$3.1B$4.9B—report ↗
2024-Q2$12.9B$3.0B$6.9B—report ↗
2024-Q1$12.7B$2.8B——report ↗
2023-Q2$11.4B$2.7B$5.7B—report ↗
2022-Q2$10.8B$2.5B$4.8B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$58.7B$14.2B$5.7B—report ↗

AstraZeneca reported FY 2025 revenue of $58,739M, up 8.6% YoY, with R&D spend of $14,232M, up 4.8% YoY. Cash and equivalents stood at $5,741M, and the company reported net income of $10,233M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$54.1B$13.6B$5.7B—report ↗
2023-FY$45.8B$10.9B$6.0B—report ↗
2022-FY$44.4B$9.8B$6.4B—report ↗
2021-FY$37.4B$9.7B$6.4B—report ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($3K), 1 sale ($2.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Sharma Mani · See remarksAward / grant1$186.24$186Form 4
2026-10-06Sharma Mani · See remarksAward / grant2$159.80$320Form 4
2026-09-08Sharma Mani · See RemarksAward / grant1$162.60$163Form 4
2026-08-08Sharma Mani · See RemarksOpen-market purchase20.233$160.57$3KForm 4
2026-08-06Sharma Mani · SVP, Group ControllerAward / grant2$163.34$327Form 4
2026-07-06Sharma Mani · See RemarksAward / grant2$190.43$381Form 4
2026-06-08Sharma Mani · See RemarksAward / grant1$179.75$180Form 4
2026-05-20Sharma Mani · See RemarksOpen-market sale11,893$185.78$2.2MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,301 reporting institutions held 747.8M shares ($143.3B, 48.2% of shares outstanding).

#InstitutionSharesValue
1INVESTOR AB51,587,810$10.2B
2VANGUARD CAPITAL MANAGEMENT LLC45,040,142$8.8B
3Capital International Investors34,393,013$6.7B
4FMR LLC29,601,724$5.8B
5Capital World Investors28,264,580$5.5B
6Legal & General Group Plc25,849,978$5.0B
7WELLINGTON MANAGEMENT GROUP LLP23,751,085$4.6B
8BANK OF AMERICA CORP /DE/19,058,327$3.8B
9VANGUARD ASSET MANAGEMENT, Ltd18,535,315$3.6B
10JPMORGAN CHASE & CO18,590,922$3.6B
11PRIMECAP MANAGEMENT CO/CA/18,213,708$3.6B
12FRANKLIN RESOURCES INC17,792,161$3.5B
13PRUDENTIAL PLC16,506,300$3.2B
14Amundi15,386,149$3.0B
15VANGUARD FIDUCIARY TRUST CO13,195,178$2.6B